FCM
VIVO

Freshford Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Freshford Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-484,176
Closed -$14.7M – 27
2022
Q2 		$14.7M Buy
+484,176
New +$13.1M 2.01% 18

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freshford Capital Management's VIVO Position: Q3 2022 in Review

Freshford Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 484,176 shares — an estimated $14.7M sold.

Freshford Capital Management first reported a position in VIVO in Q2 2022 and held it in 1 quarter. The position peaked at $14.7M in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Freshford Capital Management reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Freshford Capital Management sold 484,176 Meridian Bioscience Inc shares in Q3 2022, an estimated $14.7M.
  • Freshford Capital Management first reported a position in Meridian Bioscience Inc in Q2 2022 and held it in 1 quarter.
  • Freshford Capital Management's Meridian Bioscience Inc position peaked at $14.7M in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Freshford Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.